Literature DB >> 228336

Sensitivity of morphine-tolerant rats to muscarinic and dopaminergic agonists: relation to tolerance or withdrawal.

M J Christie, D H Overstreet.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 228336     DOI: 10.1007/bf00491974

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  36 in total

1.  Calcium-dependent protein modulator of cyclic nucleotide phosphodiesterases from mouse epidermis.

Authors:  A W Murray; A Rogers
Journal:  Biochem J       Date:  1978-12-15       Impact factor: 3.857

2.  Alterations of dopaminergic neurotransmission after chronic morphine treatment: pre- and postjunctional studies in striatal tissue.

Authors:  A Bosse; K Kuschinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-07       Impact factor: 3.000

3.  Hypersensitivity to noradrenaline in cortex after chronic morphine: relevance to tolerance and dependence.

Authors:  C Llorens; M P Martres; M Baudry; J C Schwartz
Journal:  Nature       Date:  1978-08-10       Impact factor: 49.962

4.  Two binding sites for 3H-spiroperidol on rat striatal membranes.

Authors:  M Briley; S Z Langer
Journal:  Eur J Pharmacol       Date:  1978-08-01       Impact factor: 4.432

5.  Changes in sensitivity to apomorphine during morphine dependence and withdrawal in rats.

Authors:  B Cox; M Ary; P Lomax
Journal:  J Pharmacol Exp Ther       Date:  1976-03       Impact factor: 4.030

6.  Characterization of two forms of beef heart cyclic nucleotide phosphodiesterase.

Authors:  R J Hrapchak; H Rasmussen
Journal:  Biochemistry       Date:  1972-11-21       Impact factor: 3.162

7.  Supersensitivity and dependence.

Authors:  H O Collier
Journal:  Nature       Date:  1968-10-19       Impact factor: 49.962

8.  Tolerance to the behavioral and neurochemical effects of haloperidol and morphine in rats chronically treated with morphine or haloperidol.

Authors:  S K Puri; H Lal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

9.  Elevation of brain dopamine during naloxone-precipitated withdrawal in morphine-dependent mice and rats.

Authors:  E T Iwamoto; I K Ho; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1973-12       Impact factor: 4.030

10.  Enhanced affinity of opiate receptors for naloxone in striatal slices of morphine-dependent mice.

Authors:  T Kitano; A E Takemori
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1977-10
View more
  6 in total

1.  Withdrawal from repeated morphine sensitizes mice to the striatal dopamine release enhancing effect of acute morphine.

Authors:  J Airio; M Attila; T Leikola-Pelho; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

2.  The effect of melanotrophin release inhibiting factor (MIF) and cyclo (Leu-Gly) on the tolerance to morphine-induced antinociception in the rat: a dose-response study.

Authors:  H N Bhargava
Journal:  Br J Pharmacol       Date:  1981-04       Impact factor: 8.739

3.  Morphine dependence and dopaminergic activity: tests of circling responses in rats with unilateral nigral lesions.

Authors:  J V Halliwell; R Kumar
Journal:  Br J Pharmacol       Date:  1980-12       Impact factor: 8.739

4.  Selective breeding for diisopropyl fluorophosphate-sensitivity: behavioural effects of cholinergic agonists and antagonists.

Authors:  D H Overstreet; R W Russell
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

5.  Binding of [3H]-pilocarpine to membranes from rat cerebral cortex.

Authors:  B Hedlund; T Bartfai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-09       Impact factor: 3.000

6.  Rewiring of neuronal networks during synaptic silencing.

Authors:  Jana Katharina Wrosch; Vicky von Einem; Katharina Breininger; Marc Dahlmanns; Andreas Maier; Johannes Kornhuber; Teja Wolfgang Groemer
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.